NCT04303858 - A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | Biotech Hunter

Enrollment

189

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

January 28, 2026

Study Completion Date

August 15, 2026

Conditions

Solid Tumors

Interventions

DRUG

Eciskafusp Alfa

Participants will be administered eciskafusp alfa in different schedules.

DRUG

Atezolizumab

Participants will be administered 1200 mg of atezolizumab once every 3 weeks.

Trial Locations (13)

1200

Cliniques Universitaires St-Luc, Brussels

2100

Rigshospitalet, København Ø

2730

Herlev Hospital, Herlev

3000

UZ Leuven Gasthuisberg, Leuven

28040

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

31008

Clinica Universitaria de Navarra, Pamplona

1066 CX

NKI/AvL, Amsterdam

3015 GD

Erasmus MC, Rotterdam

80-214

Uniwersyteckie Centrum Kliniczne, Gda?sk

02-781

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie, Warsaw

08003

Hospital del Mar, Barcelona

08035

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

08036

Hospital Clinic Barcelona, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY